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ABSTRACT 
T cells engineered to express chimeric antigen receptors (CARs) combining an external antibody binding domain with 
the CD3ζ T cell receptor (TCR) signaling domain for triggering cell activation are being used for immunotherapeutic 
targeting of tumor cells in a non-HLA restricted manner. In this study we transduced T cells with a CD19-CAR con- 
struct containing a truncated CD34 gene (tCD34) marker and used these to target the B cell antigen CD19 on the sur- 
face of a Hodgkin’s lymphoma (HL) cell line (L591) both in vitro and in vivo. Levels of tCD34 expression in trans- 
duced peripheral blood mononuclear cells (PBMCs) ranged from 6% - 20% and this was increased to 82% after selec- 
tion for transduced tCD34+ cells. In vitro cytotoxicity testing on a CD19+ HL cell line (L591) showed specific cell lysis 
initiated by the CD19-CAR transduced PBMCs. Importantly, CD19-CAR T cells prevented the growth of L591 HL 
tumor cells when co-injected subcutaneously (sc) in 6/6 severe combined immunodeficient (SCID) mice. There was no 
evidence of anti-tumor activity when CD19-CAR T cells were infused intravenously (iv) at the same time as L591 HL 
tumor cells were injected sc. However, 3/6 SCID mice showed tumor rejection within 83 days after iv infusion of 
CD19-CAR T cells 3 - 9 days after establishment of L591 HL tumors, while all control animals succumbed to tumors 
within 60 days. Interestingly, immuno-histochemical analysis of L591 HL tumors demonstrated that CD19-CAR T cells 
were detected not earlier than 11 days after infusion within the tumor mass. These results suggest that CD19 is a poten- 
tially attractive target for the immunotherapy of HL. 
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1. Introduction 
Hodgkin’s lymphoma (HL) is the most common lym- 
phoma in young people in industrialised countries, with 
around 1500 new cases diagnosed per year in the UK. It 
is unusual histologically in that less than 2% of the tumor 
is made up of the malignant B cells; mononuclear Hodg- 
kin or multinuclear Reed-Sternberg cells (collectively 
referred to as HRS cells). The remaining tumour bulk 
consists of a non-neoplastic infiltrate of leucocytes in- 
cluding lymphocytes and prominent eosinophils. In 
western countries, up to 50% of HL is associated with 
Epstein-Barr virus (EBV), a ubiquitous gamma-herpes- 
virus which persists for life in B lymphocytes of the host 
after primary infection [1]. In EBV-positive HL, HRS 
cells express a limited number of latent EB viral genes 
including the viral oncogene latent membrane protein  
(LMP)-1. HL is one of the most treatable adult cancers  
with over 80% of patients achieving complete remission 
following chemotherapy and/or radiotherapy. However, a 
proportion of patients have resistant primary disease and 
up to a third of those achieving remission later relapse. 
Alternative therapies are required to treat these patients. 
Immunotherapy of EBV-associated malignancies us- 
ing adoptive transfer of autologous or allogeneic vi- 
rus-specific cytotoxic T lymphocytes (CTLs) has proven 
successful, especially in the treatment of post-transplant 
lymphoproliferative disease (PTLD) [2-4]. Disappoint- 
ingly, despite being well tolerated, this form of T cell 
therapy has proven less effective in the treatment of EBV 
positive HL [5]. This poor response is possibly because 
HRS cells lack expression of EBV nuclear antigens 3a, b, 
c, the immunodominant antigens for CD8 T cells, which  
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are expressed in most PTLDs. Additionally, the non- 
neoplastic leucocyte infiltrate characteristic of HL tu- 
mors contains Th2 and T regulatory cells and is generally 
devoid of Th1 cells, CD8+ T cells and NK cells [6] 
which might mount an anti-tumor immune response. 
HRS cells appear to maintain this suppressive milieu by 
the secretion of Th2-type chemokines such as the thy- 
mus and activation regulated chemokine (TARC) [7] and 
cytokines like IL10 that inhibit Th1 responses [8]. 
One strategy which has been developed to surmount 
this tumor immune evasion is the use of engineered T 
cells that express chimeric antigen receptors (CARs), 
otherwise known as T-bodies [9]. These molecules gen- 
erally contain an antibody-based external domain such as 
the single chain variable fragment (scFv), and a TCR- 
derived internal domain for signal transduction and T cell 
activation [10]. They are expressed on the surface of T 
cells as a single gene-encoded homodimer. Advantages 
of this strategy include the ability of therapeutic cells to 
traffic to tumor sites, and to expand and persist in re- 
sponse to target recognition. Also, the MHC-independent 
recognition of targets circumvents the necessity for do- 
nor/recipient HLA matching and the propensity of tumor 
cells to down-regulate antigen presentation. Cells engi- 
neered with CARs directed against a range of tumor as- 
sociated antigens have been shown to be capable of spe- 
cific tumor cell lysis in vitro, including those targeted at 
CD19, CD30, HER2/neu and prostate-specific membrane 
antigen [11-14]. T-cells bearing first generation CARs 
(CD3 only signaling domain) are highly efficacious in 
mouse models of B-cell lymphoma [15,16] but, to date, 
there are no published studies investigating the potency 
of CAR T-cells targeting CD19 to control the growth of 
HL cells. 
CD19 is a signaling molecule expressed at all stages of 
B cell development until terminal differentiation into 
plasma cells [17], and is constitutively expressed in 
B-non Hodgkin’s lymphomas (NHL), and on the major- 
ity of chronic lymphocytic leukaemias (CLL) and acute 
lymphoblastic leukaemias (ALL) [18]. CD19-specific 
CAR (CD19-CAR) engineered T cells have been shown 
to specifically lyse the CD19+ ve Raji (Burkitt’s lym- 
phoma) cell line, CLL and ALL cells, as well as NHL 
lymph node tumor biopsy cells [11,19,20]. Expression of 
CD19 is not consistently observed in HL, however a 
variable percentage of classical HL biopsies (0 to 75%) 
and cell lines (20% to 30%) express the marker [21-24], 
and thus there is potential for the use of CD19-CAR T 
cells in the therapy of HL. 
Here we show how a CAR construct incorporating a 
CD19-specific scFv linked to a CD3ζ signaling domain 
was used to engineer CD19-specificity in T cells. These 
cells were able to target and kill HL-derived cells via 
CD19 in both an in vitro cytotoxicity assay and a SCID 
mouse model of HL. 
2. Materials and Methods 
2.1. Blood Donors 
Anonymised buffy coat donations were provided by the 
Scottish National Blood Transfusion Service (SNBTS) 
from registered blood donors with informed consent. 
Heparin (1000 IU into 50 mL; CP Pharmaceuticals, 
Wrexham, UK) was added to buffy coat samples, and 
peripheral blood mononuclear cells (PBMCs) were sepa- 
rated using Histopaque-1077 (Sigma, Irvine, UK). PBMCs 
were washed in RPMI 1640 (Invitrogen), and then cryo- 
preserved in 10% dimethyl sulphoxide (Sigma) in fetal 
bovine serum (FBS). 
2.2. Cell Lines 
Cell lines used in the study included the HL cell line 
L591 [25]. Lymphoblastoid cell lines (LCLs) were de- 
rived by in vitro EBV infection of PBMCs from healthy 
donors. The Epstein Barr Virus (EBV)-specific CTL-A 
was produced as described [26] using PBMCs from a 
donor (HLA type: A1, A3, B35, B57). This CTL was 
chosen as it matched the HLA type of L591 cells (A1, 
A33, B8, B35) at two loci. 
2.3. Cell Culture 
Culture media was supplied by Invitrogen (Paisley, UK) 
unless otherwise stated. Cells were cultured in RPMI 
1640 supplemented with 2 mM L-glutamine, 100 U/mL 
penicillin, 100 U/mL streptomycin and FBS (Perbio) at 
10% v/v (LCL) or 20% v/v (transduced PBMCs, L591, 
PG13, CTL-A). 
2.4. scFv Construct and Retroviral Production 
The chimeric receptor construct was composed of a 
CD19 specific scFv isolated from the HD37 hybridoma, 
a flexible hinge region, and the transmembrane and in- 
tracellular signaling domains of CD3ζ [11]. A truncated 
CD34 (tCD34) gene was included as a marker of trans- 
duction. The construct was codon optimised and cloned 
into the pMP71 retroviral vector [27]. An empty vector 
with the expression cassette replaced by green fluores- 
cent protein (GFP) was used as a virus control. Virus was 
collected from the PG13 packaging cell line stably ex- 
pressing the construct as previously described [27]. 
2.5. T Cell Transduction 
PBMCs were thawed and washed twice by centrifugation 
in RPMI with 20% FBS, first at 800 g for 8 min, then 
400 g for 7 min. Cells were activated with 1 µg/mL anti- 
CD3 (Becton Dickinson) and 1 µg/mL anti-CD28 (Bec-  
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ton Dickinson) in complete RPMI for 72 hours. Acti- 
vated PBMCs were resuspended in undiluted virus su- 
pernatant (MOI of approximately 1.5) with 6 µg/mL 
polybrene (Sigma) and centrifuged at 1200 g and 4˚C for 
3 hours. Transduced cells were resuspended at approxi- 
mately 5 × 105 cells/mL in medium supplemented with 
100 IU/mL IL-2 (UDG) and cultured overnight. Trans- 
duction was repeated the following day. Transduced cells 
were cultured for up to 2 weeks, with IL-2 (100 IU/mL) 
added to the culture three times a week. 
2.6. Selection Protocols 
EasySep systems (StemCell Technologies) were used to 
separate cell populations on the basis of cell surface an- 
tigen expression, following the manufacturer’s instruct- 
tions. Briefly, cells were washed in cell separation buffer 
(CSB) at 180 g for 7 minutes and resuspended at 1 × 108 
cells/mL in CSB. EasySep positive selection cocktail was 
added at a concentration of 100 µL/mL cells for CD56 
selection and 200 µL/mL cells for CD34 selection, and 
the mixture incubated for 15 minutes at room tempera- 
ture. Nanoparticles were added at a concentration of 50 
µL/mL, and the mixture incubated for 10 minutes at 
room temperature. Total volume was brought to 2.5 mL 
with CBS and the tube placed in an EasySep magnet for 
5 minutes. The supernatant was poured off, the tube re- 
moved from the magnet, 2.5 mL CSB added to the re- 
maining cells, and the tube placed back in the magnet. 
The separations were repeated a total of 4 times for 
CD34 and 3 times for CD56 selection. 
2.7. Flow Cytometry 
Cells to be analysed were washed twice in PBSA (1% 
w/v BSA, 0.1% w/v sodium azide, 0.2% w/v EDTA) by 
centrifugation at 120 g for 5 minutes. The supernatant 
was decanted and cells resuspended in residual liquid. 10 
µL of the appropriate antibody was added and the tubes 
incubated for 20 minutes at 4˚C in the dark. The anti- 
bodies used were anti-CD4 (clone RPA-T4), anti CD8 
(clone RPA-T8), anti-CD19 (clone HIB19), and CD34 
(clone 582) and anti CD56 (clone B159), all supplied by 
Becton Dickinson. Cells were washed twice in PBSA 
then resuspended in 1 × CellFix (Becton Dickinson) and 
evaluated on either a FACScan (Becton Dickinson) or 
FACSCalibur (Becton Dickinson) flow cytometer. At 
least 10,000 events were acquired for each sample. 
2.8. Cytotoxicity Assay 
Cytotoxic activity in vitro was measured using a standard 
chromium (Cr) release assay [28]. Cells from each target 
cell line were labelled with 51Cr for 1 hour at 37˚C before 
plating with effector cells at an effector: target ratio of 
20:1, 10:1 and 5:1. After incubation at 37˚C for 4 hours 
the release of 51Cr from lysed cells was measured on a 
gamma counter. Spontaneous release was calculated by 
incubating target cells without effector cells, and maxi- 
mum release calculated by lysing target cells with 1% 
Triton-X (Sigma). 
2.9. Mouse Model 
CB17 scid/scid mice were supplied and maintained by 
the University of Edinburgh Biological Services Unit. 
All animal work was carried out in full compliance with 
the Animals (Scientific Procedures) Act 1986. Tumor 
cells were inoculated subcutaneously (sc) in the flank. 
Engineered cells were delivered sc or intravenously (iv) 
by tail vein injection. Mice were observed daily for signs 
of illness and sc tumor formation. Using callipers, mac- 
roscopic sc tumors were measured in 2 planes 90˚ to each 
other; tumor volume (mm3) calculated using the formula 
ab2/2 (a: length; b: width). Animals were observed for up 
to 100 days. 
2.10. Immunohistochemistry 
Formalin-fixed tissue samples were embedded in paraffin 
wax and cut into 4 m sections. Antigen retrieval was 
performed on hydrated sections by immersing in 1 L of 
pH 6 10 mM citric acid and microwaving at full power 
(800 W) for 25 minutes, followed by 15 minutes cooling. 
Endogenous peroxidase was blocked using 0.03% hy- 
drogen peroxide for 10 minutes, followed by a non spe- 
cific blocking step using 10% goat serum (GS) for 20 
mins prior to antibody incubation. The CD34 antibody 
(Dako M7165) was used at a dilution of 1 g/mL with 
the Animal Research Kit (Dako K3954), as per instruct- 
tions. Incubation with the biotinylated CD34 antibody for 
15 minutes is followed by detection with streptavidin 
peroxidase and DAB. Nuclei were counterstained with 
Gill 1 haematoxylin (Thermo-Electron, Runcorn, UK). 
2.11. Statistics 
Data are presented as mean ± standard deviation (SD). 
The non-parametric Mann Whitney t test was used to 
compare levels of specific lysis in chromium release as- 
says. Fisher’s exact test for comparison of proportions, 
and Wilcoxon rank sum test for comparison of two 
groups, was used to analyse immunotherapy data. In all 
cases, p < 0.05 was accepted as indicating a significant 
difference. Tests were carried out using Prism 4.0 for 
Windows (GraphPad). 
3. Results 
3.1. T Cell Transduction 
Stored donor PBMCs were thawed and transduced with 
the retroviral vector encoding the chimeric anti-CD19 
receptor. Transduced cells were cultured for up to two 
weeks in IL-2 containing media. In six experiments cell 
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expansion over the two week period averaged 84-fold 
(range 50- to 120-fold). Transduction levels were deter- 
mined using flow cytometery and staining for the tCD34 
molecule included in the vector. The average level of 
transduction from experiments on three different PBMC 
donors was 13% ± 6% (range 6% - 20%). At the end of 
the culture period, cells were predominantly CD8+ ve 
(57% ± 6%), with minority CD4+ ve (39% ± 4%) and 
CD56+ ve (14% ± 4%). 
3.2. In Vitro Cytotoxicity 
T cells transduced with the CD19-CAR were tested for 
cytotxic activity using a standard four hour chromium 
release assay in 5 repeat experiments (Figure 1). The 
targets used were the CD19-expressing HL cell line L591, 
and a CD19-positive LCL. Mock transduced PBMCs 
were used as a negative control, and the EBV specific 
CTL-A was used as a positive control. At effector:target 
ratios of 20:1, 10:1 and 5:1 specific lysis of both target 
cell lines by the CD19-CAR transduced cells and CTL-A 
was observed. Lysis by CD19-CAR transduced cells was 
significantly higher than that effected by mock 
transduced cells at all effector to target ratios. At 20:1, T 
cells expressing the CD19-CAR receptor lysed the L591 
cell line at 24% ± 11% (range 12% - 35%), and the LCL 
 
 
Figure 1. Specific lysis of the L591 and LCL target lines by 
CD19-CAR engineered T cells and CTL-A was significantly 
higher at all effector:target (E:T) ratios than that achieved 
by mock transduced cells in a 51Cr release assay. Bars show 
mean ± SD for five experiments. 
at 29% ± 13% (range 12% - 44%), compared with mock 
transduced cells at 5% ± 3% (range 2% - 9%) and 3% ± 
2% (range 1% - 6%). 
In an attempt to increase the level of T cell trans- 
duction, a population of CD19-CAR transduced cells was 
enriched using positive selection for the tCD34 marker. 
Before selection, 8% of cells expressed tCD34, and fol- 
lowing selection the depleted and enriched fractions 
contained 1% and 82% transduced cells respectively. 
Increasing the fraction of transduced cells in the total 
population improved levels of specific lysis (Figure 2). 
When the percentages of tCD34+ cells in CD19-CAR 
transduced cells, the tCD34-depleted fraction, and the 
tCD34-enriched fraction were 8%, 1% and 82%, respec- 
tively, specific lysis at an effector to target ratio of 20:1 
of L591 cells was 12%, 10%, and 21%, respectively, 
while specific lysis of LCLs was 12%, 7%, and 41%, 
respectively. 
3.3. In Vivo Tumor Prevention 
T cells transduced with the CD19-CAR were assessed for 
their ability to prevent tumor formation in an in vivo HL 
model. Groups of 6 SCID mice received sc injection of 5 
 
 
Figure 2. Effect of transduced cell numbers on in vitro cy-
totoxicity. Specific lysis of the L591 and LCL target lines by 
CD19-CAR engineered T cells was improved in a 51Cr re-
lease assay after the culture was enriched by selection of 
CD19-CAR cells using tCD34 as a marker of transduction. 
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× 106 L591 cells concurrently with sc or iv inoculation of 
either 5 × 107 CD19-CAR engineered cells or CTL-A 
cells (an EBV-specific CTL, matching two MHC loci 
with L591). Seventeen out of 22 (77%) control animals 
that received no therapy developed sc tumors as a result 
of sc injection of 5 × 106 L591 cells. Time to tumors on- 
set (Table 1) was monitored and compared between 
groups. Whilst mice given CTL-A cells sc developed 
tumors at a rate that was not statistically different to con- 
trol mice [4/6 (67%) vs 17/22 (77%)], none of the mice 
that received CD19-CAR sc developed tumors [0/6 (0%); 
Fisher’s exact test: p = 0.001]. Conversely, administra- 
tion of CD19-CAR-transduced cells via the iv route did 
not significantly affect tumor development, with 4 out of 
6 (67%) iv CD19-CAR treated mice developing tumors 
(Fisher’s exact test: p = 0.6219). Interestingly, median 
time to tumor in untreated mice was 20 days compared 
with 29 days in iv administered CD19-CAR treated mice 
although this was not a significant difference (Wilcoxon 
rank sum test: p = 0.0625). Of the four mice treated with 
iv administered CD19-CAR cells that developed sc tu- 
mors, three showed sustained tumor growth which did 
not differ from control animals whereas one mouse had 
completely cleared its tumor burden by day 64 post in- 
jection. Of the 17 control animals that developed sc tu- 
mors, none showed spontaneous tumor regression over 
an observation period of 100 days. 
3.4. In Vivo Tumor Therapy 
The ability of CD19-CAR engineered T cells to treat 
established sc L591 tumors was also tested. Six tu- 
mor-bearing SCID mice were injected iv with 5 × 107 
engineered cells between three and nine days after first 
signs of visible sc tumor formation, which was 19 to 25 
days following sc injection of L591 tumor cells, and 
subsequent tumor growth observed (Figure 3). Three 
mice were culled prior to the conclusion of the experi- 
ment due to skin necrosis at the tumor site, their lesions 
displaying sustained tumor growth up to time of culling. 
The remaining three mice had completely cleared their 
tumor burden by 65, 69 and 83 days post L591 injection. 
This was a significant effect when compared with the 17  
 
Table 1. Tumor incidence in HL SCID mice given prophy-
lactic immunotherapy. 
Treatment 
Cell line Route 
Number of mice  
with tumor 
Median days to  
tumor onset (range) 
None - 17/22 20 (16 - 28) 
CD19-CAR sc 0/6* - (-) 
CD19-CAR iv 4/6 29 (21 - 33) 
CTL-A sc 4/6 27 (26 - 28) 
*indicates significant effect (p = 0.001). 
 
(a) 
 
(b) 
Figure 3. Tumor growth curves of SCID mice bearing sc 
tumors derived from HL L591 cells, either with no thera-
peutic intervention (a), or treated with CD19-CAR trans-
duced T cells (b). Complete tumor regression was observed 
in three of six treated mice, which was not seen in any con-
trol mice. Each line represents an individual mouse. 
 
untreated mice with established tumors derived from 
L591 cells which showed no tumor regression (Fisher’s 
exact, p = 0.011). 
In a time course experiment to investigate trafficking 
of transduced CAR cells to the sc tumour site, five tu- 
mour-bearing SCID mice were injected iv with 5 × 107 
CD19-CAR engineered cells. A single mouse was culled 
on days 1, 4, 7, 11, and 18 post treatment and immuno- 
histochemistry performed on tumour sections. Anti- 
CD34 antibodies were used to detect transduced human 
T cells infiltrating the tumours. tCD34+ cells were seen 
in tumour sections on day 11 and 18 post treatment, but 
not days 1, 4 or 7. Tumor tissue taken on days 11 and 18 
showed 8% and 41% of the total cell population positive 
for tCD34 respectively (Figure 4). 
4. Discussion 
The results demonstrate that activated PBMCs trans- 
duced with a retroviral vector to express a CAR specific  
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Day 1 
Day 4 
Day 7 
Day 11 
 
Day 18 
 
Figure 4. Immunostaining showing tCD34+ cells in L591 
tumors treated with CD19-CAR transduced PBMCs at day 
11 and 18, but not days 1, 4 or 7 post infusion.  HRP detec-
tion system shows positive brown membrane staining. Ar-
rows indicate individual positive cells. Sections were 
counterstained with haematoxylin. 
 
for CD19 are capable of specific lysis of CD19+ ve HL 
target cells in an in vitro cytotoxicity assay and can me- 
diate significant tumor regression in an in vivo model of 
HL. 
Levels of retrovirus transduction varied between 6% - 
20%, with a mean of 13% ± 6% cells expressing CD34 
as a marker of transduction. Increasing the fraction of 
transduced cells in the total population by CD34 selec- 
tion improved levels of specific lysis (Figure 2). How- 
ever there was not a simple relationship between number 
of CD34+ cells and level of specific lysis. Others have 
also observed that levels of T cell transduction do not 
correlate with absolute levels of target cell lysis [11], 
suggesting that it may not be necessary to achieve high 
levels of expression of the CAR to induce a therapeutic 
response. Indeed the relationship between transduction 
rates and specific lysis in in vitro assays and the in vivo 
effect of engineered cells is unclear. Whilst we observed 
significant target cell lysis by a CTL line (CTL-A) in 
vitro, this didn’t correspond to tumor prevention in vivo 
(Table 1 and Figure 1). In a clinical trial using EBV- 
specific CTLs to treat PTLD, no correlation was found 
between levels of specific lysis as measured by 51Cr re- 
lease assays and tumor response [3]. It remains to be seen 
whether this is also the case when the therapeutic cells 
are directed against a single epitope via a CAR rather 
than multiple CTL specificities. 
The aim of this cellular immunotherapy is to produce 
engineered T cells that home to primary and metastatic 
tumor sites to give an immediate effect on tumor burden 
as well as persisting and proliferating to protect against 
disease relapse. In our experiments the SCID mouse tu- 
mors continued to increase in size for up to 10 days after 
infusion of the engineered T cells before showing signs 
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of regression (Figure 3), and tCD34+ T cells were not 
detectable in tumors until day 11 post infusion (Figure 4). 
It is possible that the transduced cells required a period 
of expansion before migrating to the tumor site in suffi- 
cient numbers to effect a clinical response. This may also 
explain why no significant effect was seen in mice that 
received iv engineered T cells on the same day as tumor 
cells but were effective in mice which received T cells 
after tumor formation (it is possible that a minimum tu- 
mor volume is required before effective migration and 
stimulation of transduced T-cells can be achieved). By 
day 18 post infusion, the level of transduced cells in the 
tumor (41%) was high and these cells were able to effect 
complete tumor regression in 50% of SCID mice carry- 
ing an established HL tumor with tumor regression be- 
ginning at the time of high T-cell infiltration. In addition 
several animals were culled due to necrosis of the skin at 
the tumor site rather than tumor progression perse. This 
unusual response may have been caused by an inflame- 
matory response initiated by the T cell themselves, and it 
is possible that a higher dose of cells would have pro- 
duced a more rapid treatment effect and avoided this 
complication. 
In summary, this study demonstrates that CD19-CAR 
T cell adoptive therapy may be a suitable approach to 
target Hodgkin lymphoma. Recent studies demonstrating 
spectacular anti-tumor responses in three patients with 
advanced chronic lymphocytic leukaemia (CLL) treated 
with CD19-CAR T cells highlights the strong potential 
for this form of therapy [29,30]. In this study, a second 
generation CAR consisting of the CD137 (4-1BB) fused 
to the CD3 signalling chain was used together with len- 
tiviral gene transfer and advanced ex vivo T cell culture 
systems. Other studies using retroviral vectors encoding 
CAR’s employing CD28-CD3 second generation CAR’s 
are also underway to challenge CLL [31,32]. Exploring 
these technological developments to deliver an optimised 
CAR-T cell therapy for Hodgkins Lymphoma clearly 
warrants further examination. 
5. Acknowledgements 
This work was supported by grant CZB/4/521 from the 
Chief Scientist Office (CSO), Scotland. We would like to 
acknowledge Garry Ashton and Caron Abbey at the 
Paterson Institute for Cancer Research histology lab for 
help with immunohistochemistry. 
REFERENCES 
[1] A. B. Rickinson and E. Kieff, “Epstein-Barr Virus,” In: D. 
Knipe and P. Howley, Eds., Fields Virology, Lippincott 
Williams and Wilkins, Philadelphia, Vol. 2. 2007, pp. 
2655-2700. 
[2] C. M. Bollard, C. M. Rooney and H. E. Heslop, “T-Cell 
Therapy in the Treatment of Post-Transplant Lymphopro- 
liferative Disease,” Nature Reviews Clinical Oncology, 
2012 (in press). 
[3] T. Haque, G. M. Wilkie, M. M. Jones, C. D. Higgins, G. 
Urquhart, P. Wingate, D. Burns, K. McAulay, M. Turner, 
C. Bellamy, P. L. Amlot, D. Kelly, A. Macgilchrist, M. K. 
Gandhi, A. J. Swerdlow and D. H. Crawford, “Allogeneic 
Cytotoxic T Cell Therapy for EBV-Positive Post Trans- 
plant Lymphoproliferative Disease: Results of a Phase II 
Multicentre Clinical Trial,” Blood, Vol. 110, No. 4, 2007, 
pp. 1123-1131. doi:10.1182/blood-2006-12-063008  
[4] C. M. Rooney, C. A. Smith, C. Y. Ng, S. Loftin, C. Li, R. 
A. Krance, M. K. Brenner and H. E. Heslop, “Use of 
Gene-Modified Virus-Specific T Lymphocytes to Control 
Epstein-Barr-Virus-Related Lymphoproliferation,” Lan- 
cet, Vol. 345, No. 8941, 1995, pp. 9-13.  
doi:10.1016/S0140-6736(95)91150-2 
[5] C. M. Bollard, L. Aguilar, K. C. Straathof, B. Gahn, M. H. 
Huls, A. Rousseau, J. Sixbey, M. V. Gresik, G. Carrum, 
M. Hudson, D. Dilloo, A. Gee, M. K. Brenner, C. M. 
Rooney and H. E. Heslop, “Cytotoxic T Lymphocyte 
Therapy for Epstein-Barr Virus+ Hodgkin’s Disease,” 
Journal of Experimental Medicine, Vol. 200, No. 12, 
2004, pp. 1623-1633. doi:10.1084/jem.20040890 
[6] S. Poppema, “Immunobiology and Pathophysiology of 
Hodgkin Lymphomas,” Hematology American Society of 
Hematology Education Program Book, Vol. 2005, No. 1, 
2005, pp. 231-238. doi:10.1182/asheducation-2005.1.231 
[7] A. van den Berg, L. Visser and S. Poppema, “High Ex- 
pression of the CC Chemokine TARC in Reed-Sternberg 
Cells. A Possible Explanation for the Characteristic 
T-Cell Infiltratein Hodgkin’s Lymphoma,” The American 
Journal of Pathology, Vol. 154, No. 6, 1999, pp. 1685- 
1691. doi:10.1016/S0002-9440(10)65424-7 
[8] H. Herbst, H. D. Foss, J. Samol, I. Araujo, H. Klotzbach, 
H. Krause, A. Agathanggelou, G. Niedobitek and H. Stein, 
“Frequent Expression of Interleukin-10 by Epstein-Barr 
Virus-Harboring Tumor Cells of Hodgkin’s Disease,” 
Blood, Vol. 87, No. 7, 1996, pp. 2918-2829.  
[9] Z. Eshhar, T. Waks, G. Gross and D. G. Schindler, “Spe- 
cific Activation and Targeting of Cytotoxic Lymphocytes 
through Chimeric Single Chains Consisting of Anti- 
body-Binding Domains and the Gamma or Zeta Subunits 
of the Immunoglobulin and T-Cell Receptors,” Pro- 
ceedings of the National Academy of Sciences, Vol. 90, 
No. 2, 1993, pp. 720-724. doi:10.1073/pnas.90.2.720 
[10] Z. Eshhar, T. Waks, A. Bendavid and D. G. Schindler, 
“Functional Expression of Chimeric Receptor Genes in 
Human T Cells,” Journal of Immunological Methods, Vol. 
248, No. , 2001, pp. 67-76.  
doi:10.1016/S0022-1759(00)00343-4 
[11] E. J. Cheadle, D. E. Gilham, F. C. Thistlethwaite, J. A. 
Radford and R. E. Hawkins, “Killing of Non-Hodgkin 
Lymphoma Cells by Autologous CD19 Engineered T 
Cells,” British Journal of Haematology, Vol. 129, No. 3, 
2005, pp. 322-332.  
doi:10.1111/j.1365-2141.2005.05456.x 
[12] M. C. Gong, J. B. Latouche, A. Krause, W. D. Heston, N. 
H. Bander and M. Sadelain, “Cancer Patient T Cells Ge- 
Copyright © 2012 SciRes.                                                                                  JCT 
Rejection of Experimental Hodgkins Lymphoma by T-Cells Engineered with a CD19 Chimeric Antigen Receptor 560 
netically Targeted to Prostate-Specific Membrane Anti- 
gen Specifically Lyse Prostate Cancer Cells and Release 
Cytokines in Response to Prostate-Specific Membrane 
Antigen,” Neoplasia, Vol. 1, No. 2, 1999, pp. 123-127.  
doi:10.1038/sj.neo.7900018 
[13] N. M. Haynes, J. A. Trapani, M. W. Teng, J. T. Jackson, 
L. Cerruti, S. M. Jane, M. H. Kershaw, M. J. Smyth and P. 
K. Darcy, “Single-Chain Antigen Recognition Receptors 
That Costimulate Potent Rejection of Established Expe- 
rimental Tumors,” Blood, Vol. 100, No. 10, 2002, pp. 
3155-3163. doi:10.1182/blood-2002-04-10411 
[14] B. Savoldo, C. M. Rooney, A. Di Stasi, H. Abken, A. 
Hombach, A. E. Foster, L. Zhang, H. E. Heslop, M. K. 
Brenner and G. Dotti, “Epstein Barr Virus-Specific Cy- 
totoxic T Lymphocytes Expressing the Anti-CD30{Zeta} 
Artificial Chimeric T-Cell Receptor for Immunotherapy 
of Hodgkin’s Disease,” Blood, Vol. 110, No. 7, 2007, pp. 
2620-2630. doi:10.1182/blood-2006-11-059139 
[15] E. J. Cheadle, R. E. Hawkins, H. Batha, D. G. Rothwell, 
G. Ashton and D. E. Gilham, “Eradication of Established 
B-Cell Lymphoma by CD19-Specific Murine T Cells Is 
Dependent on Host Lymphopenic Environment and Can 
Be Mediated by CD4+ and CD8+ T Cells,” Journal of 
Immunotherapy, Vol. 32, No. 3, 2009, PP. 207-218.  
doi:10.1097/CJI.0b013e318194a921 
[16] E. J. Cheadle, R. E. Hawkins, H. Batha, A. L. O’Neill, S. 
J. Dovedi and D. E. Gilham, “Natural Expression of the 
CD19 Antigen Impacts the Long-Term Engraftment but 
Not Antitumor Activity of CD19-Specific Engineered T 
Cells,” Journal of Immunotherapy, Vol. 184, No. 4, 2010, 
pp. 1885-1896. doi:10.4049/jimmunol.0901440 
[17] L. M. Nadler, K. C. Anderson, G. Marti, M. Bates, E. 
Park, J. F. Daley and S. F. Schlossman, “B4, a Human B 
Lymphocyte-Associated Antigen Expressed on Normal, 
Mitogen-Activated, and Malignant B Lymphocytes,” 
Journal of Immunotherapy, Vol. 131, No. 1, 1983, pp. 
244-250. 
[18] F. M. Uckun, W. Jaszcz, J. L. Ambrus, A. S. Fauci, K. 
Gajl-Peczalska, C. W. Song, M. R. Wick, D. E. Myers, K. 
Waddick and J. A. Ledbetter, “Detailed Studies on Ex- 
pression and Function of CD19 Surface Determinant by 
Using B43 Monoclonal Antibody and the Clinical Poten-
tial of Anti-CD19 Immunotoxins,” Blood, Vol. 71, No. 1, 
1988, pp. 13-29. 
[19] R. J. Brentjens, J. B. Latouche, E. Santos, F. Marti, M. C. 
Gong, C. Lyddane, P. D. King, S. Larson, M. Weiss, I. 
Riviere and M. Sadelain, “Eradication of Systemic B-Cell 
Tumors by Genetically Targeted Human T Lymphocytes 
Co-Stimulated by CD80 and Interleukin-15,” Nature 
Medicine, Vol. 9, No. 3, 2003, pp. 279-286.  
doi:10.1038/nm827 
[20] L. J. Cooper, M. S. Topp, L. M. Serrano, S. Gonzalez, W. 
C. Chang, A. Naranjo, C. Wright, L. Popplewell, A. 
Raubitschek, S. J. Forman and M. C. Jensen, “T-Cell 
Clones Can Be Rendered Specific for CD19: Toward the 
Selective Augmentation of the Graft-versus-B-Lineage 
Leukemia Effect,” Blood, Vol. 101, No. 4, 2003, pp. 
1637-1644. doi:10.1182/blood-2002-07-1989 
[21] H. G. Drexler, “Recent Results on the Biology of Hodg- 
kin and Reed-Sternberg Cells. I. Biopsy Material,” Leu- 
kemia & Lymphoma, Vol. 8, No. 4-5, 1992, pp. 283-313.  
doi:10.3109/10428199209051008 
[22] H. G. Drexler, “Recent Results on the Biology of Hodg- 
kin and Reed-Sternberg Cells. II. Continuous Cell Lines,” 
Leukemia & Lymphoma, Vol. 9, No. 1-2, 1993, pp. 1-25. 
doi:10.3109/10428199309148499 
[23] H. Herbst, G. Tippelmann, I. Anagnostopoulos, J. Gerdes, 
R. Schwarting, T. Boehm, S. Pileri, D. B. Jones and H. 
Stein, “Immunoglobulin and T-Cell Receptor Gene Rear- 
rangements in Hodgkin’s Disease and Ki-1-Positive 
Anaplastic Large Cell Lymphoma: Dissociation between 
Phenotype and Genotype,” Leukemia Research, Vol. 13, 
No. 2, 1989, pp. 103-116.  
doi:10.1016/0145-2126(89)90134-3 
[24] C. Schmid, L. Pan, T. Diss and P. G. Isaacson, “Expres- 
sion of B-Cell Antigens by Hodgkin’s and Reed-Stern- 
berg Cells,” The American Journal of Pathology, Vol. 
139, No. 4, 1991, pp. 701-707.  
[25] V. Diehl, H. H. Kirchner, H. Burrichter, H. Stein, C. 
Fonatsch, J. Gerdes, M. Schaadt, W. Heit, B. Uchanska- 
Ziegler, A. Ziegler, F. Heintz and K. Sueno, “Characteris- 
tics of Hodgkin’s Disease-Derived Cell Lines,” Cancer 
Treatment Reports, Vol. 66, No. 4, 1982, pp. 615-632.  
[26] G. M. Wilkie, C. Taylor, M. M. Jones, D. M. Burns, M. 
Turner, D. Kilpatrick, P. L. Amlot, D. H. Crawford and T. 
Haque, “Establishment and Characterization of a Bank of 
Cytotoxic T Lymphocytes for Immunotherapy of Epstein- 
Barr Virus-Associated Diseases,” Journal of Immuno- 
therapy, Vol. 27, No. 4, 2004, pp. 309-316.  
doi:10.1097/00002371-200407000-00007 
[27] E. J. Cheadle, D. E. Gilham and R. E. Hawkins, “The 
Combination of Cyclophosphamide and Human T Cells 
Genetically Engineered to Target CD19 Can Eradicate 
Established B-Cell Lymphoma,” British Journal of Hae- 
matology, Vol. 142, No. 1, 2008, pp. 65-68.  
doi:10.1111/j.1365-2141.2008.07145.x 
[28] T. Haque, P. L. Amlot, N. Helling, J. A. Thomas, P. 
Sweny, K. Rolles, A. K. Burroughs, H. G. Prentice and D. 
H. Crawford, “Reconstitution of EBV-Specific T Cell 
Immunity in Solid Organ Transplant Recipients,” Journal 
of Immunology, Vol. 160, No. 12, 1998, pp. 6204-6209.  
[29] M. Kalos, B. L. Levine, D. L. Porter, S. Katz, S. A. 
Grupp, A. Bagg and C. H. June, “T Cells with Chimeric 
Antigen Receptors Have Potent Antitumor Effects and 
Can Establish Memory in Patients with Advanced Leu- 
kemia,” Science Translational Medicine Home, Vol. 3, 
No. 95, 2011, p. 95ra73.  
doi:10.1126/scitranslmed.3002842 
[30] D. L. Porter, B. L. Levine, M. Kalos, A. Bagg and C. H. 
June, “Chimeric Antigen Receptor-Modified T Cells in 
Chronic Lymphoid Leukemia,” The New England Jour- 
nal of Medicine, Vol. 365, No. 8, 2011, pp. 725-733.  
doi:10.1056/NEJMoa1103849 
[31] R. J. Brentjens, I. Riviere, J. H. Park, M. L. Davila, X. 
Wang, J. Stefanski, C. Taylor, R. Yeh, S. Bartido, O. 
Borquez-Ojeda, M. Olszewska, Y. Bernal, H. Pegram, M. 
Przybylowski, D. Hollyman, Y. Usachenko, D. Pirraglia, 
J. Hosey, E. Santos, E. Halton, P. Maslak, D. Scheinberg, 
J. Jurcic, M. Heaney, G. Heller, M. Frattini and M. Sade- 
Copyright © 2012 SciRes.                                                                                  JCT 
Rejection of Experimental Hodgkins Lymphoma by T-Cells Engineered with a CD19 Chimeric Antigen Receptor 
Copyright © 2012 SciRes.                                                                                  JCT 
561
lain, “Safety and Persistence of Adoptively Transferred 
Autologous CD19-Targeted T Cells in Patients with Re- 
lapsed or Chemotherapy Refractory B-Cell Leukemias,” 
Blood, Vol. 118, No. 18, 2011, pp. 4817-4828.  
doi:10.1182/blood-2011-04-348540 
[32] J. N. Kochenderfer, M. E. Dudley, S. A. Feldman, W. 
H.Wilson, D. E. Spaner, I. Maric, M. Stetler-Stevenson, 
G. Q. Phan, M. S. Hughes, R. M. Sherry, J. C. Yang, U. S. 
Kammula, L. Devillier, R. Carpenter, D. A. Nathan, R. A. 
Morgan, C. Laurencot and S. A. Rosenberg, “B-Cell De-
pletion and Remissions of Malignancy along with Cyto-
kine-Associated Toxicity in a Clinical Trial of Anti-CD19 
Chimeric-Antigen-Receptor-Transduced T Cells,” Blood, 
Vol. 119, No. 12, 2012, pp. 2709-2720.  
doi:10.1182/blood-2011-10-384388 
 
 
